April 29, 2026

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transpla...

The ASCO Post

April 29, 2026

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder ca...

The ASCO Post

April 28, 2026

Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial

As reported in the Journal of Clinical Oncology by Loibl et al, long-term analysis of the German phase II GeparNuevo trial showed continued benefit in outcomes with neoadjuvant durvalumab vs placebo f...

The ASCO Post

April 28, 2026

Proton Therapy in Early-Onset Locally Advanced Rectal Cancer: The Importance of Fertility-Preserving Multimodality Care

The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.

Baptist Health South Florida

April 27, 2026

Clinical Strategies for Preserving Fertility in Male Cancer Patients

Urologist Justin Dubin, M.D., director of Men’s Sexual Health at Baptist Health Miami Cancer Institute, emphasizes that fighting cancer and preserving fertility are not mutually exclusive.

Baptist Health South Florida

April 27, 2026

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.  

The ASCO Post

April 24, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

The ASCO Post

April 24, 2026

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

The ASCO Post

April 24, 2026

POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy

For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, pres...

The ASCO Post

April 23, 2026

Long-Term Immunotherapy for Alveolar Soft Part Sarcoma

Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical t...

The ASCO Post